Cancer tests are scaling, but expectations rose
- Q1 2026 revenue grew 21%, led by a 26% rise in testing revenue.
- Decipher Prostate and Afirma are the core engine, with Q1 volumes up 24% and 12%.
- Adjusted EBITDA margin reached about 31% in Q1, well above management's long-term target.
- Testing revenue made up about 97% of Q1 revenue, so payer coverage and doctor use matter most.
- The stock now needs clean execution from Prosigna and TrueMRD, not only strong legacy tests.
A stronger core, a higher bar
Veracyte entered 2026 with clear momentum. In Q1 2026, total revenue rose 21%, testing revenue rose 26%, and diagnostic test volume rose 19%. Decipher Prostate volume grew 24%, while Afirma volume grew 12%. That is strong proof that the main business is still gaining use among doctors.
The bull case is simple. Veracyte has built a testing flywheel: publish evidence, get into medical guidelines, win payer coverage, and then sell more tests through the same doctor network. That model is now producing real profit and cash. Q1 adjusted EBITDA margin was about 31%, and management raised full-year revenue growth guidance to 13% to 14%.
The hard part is that the stock has already reacted to better results. Full-year guidance still points to slower growth than the 21% posted in Q1. The next leg depends on newer tests, especially Prosigna in U.S. breast cancer and TrueMRD in muscle-invasive bladder cancer.
Since the Q1 filing, Veracyte has moved from waiting on these catalysts to early launch mode. The key watch now is not whether the products exist, but whether doctors order them, payers reimburse them, and early sales show that they can become real growth layers.
Evidence turns into paid tests
Veracyte makes money when doctors order its cancer tests and payers, such as Medicare or insurers, pay for them. Most revenue comes from U.S. laboratory developed tests, or LDTs, which are tests designed and run inside a certified lab.
The business works best when clinical data shows that a test changes care. Decipher is the clearest example. Evidence and guideline inclusion help doctors trust it, which raises test volume. Better payer contracts and billing can also raise average selling price, often called ASP, meaning the money collected per test.
This model can break in two places. Doctors may not adopt a new test, even if the science is promising. Or payers may refuse coverage, demand prior approval, or cut rates. Because testing is nearly all of revenue, reimbursement is not a side issue. It is central to the company.
Veracyte also has a useful sales base. Its urology channel already sells Decipher Prostate, and that same channel can help launch Decipher Bladder and TrueMRD. That lowers some launch risk, but it does not remove the need for coverage decisions and proof of repeat ordering.
Core tests fund new bets
Decipher Prostate
This is the main growth driver. Q1 2026 volume grew 24%, with strong traction in higher-risk prostate cancer categories.
Afirma
Afirma helps evaluate thyroid nodules and remains a steady second pillar. Q1 2026 volume grew 12%, helped by a lower no-result rate after the move to the v2 transcriptome platform.
Decipher Bladder
This is an earlier bladder cancer test with growing adoption. It also helps Veracyte build deeper ties with urologists before TrueMRD scales.
Prosigna IVD
Prosigna is sold outside the U.S. as an in vitro diagnostic, or IVD, meaning a test kit used by local labs. Product revenue is much smaller than testing revenue and has faced supply and quality constraints.
Prosigna LDT
The U.S. Prosigna launch is the breast cancer growth option. It depends on clinical evidence, guideline progress, and share gains against established tests.
TrueMRD
TrueMRD is a minimal residual disease test, which looks for small signs that cancer may be returning. The first launch targets muscle-invasive bladder cancer and uses Veracyte's urology sales channel.
Almost all testing
The mix uses Q1 2026 revenue from the Form 10-Q. Testing was about 97% of revenue, so Decipher and Afirma carry most of the near-term result.
What could break the story
New launches fail to scale
High impact · Medium oddsThe stock now expects Prosigna LDT and TrueMRD to add growth beyond Decipher and Afirma. If early ordering is slow, 2027 growth expectations could fall. Good launch headlines are not enough if doctors do not change ordering habits.
Reimbursement pressure
High impact · Medium oddsVeracyte recognizes testing revenue based on what it expects to collect, not list price. Medicare and UnitedHealthcare together represented 47% of Q1 2026 revenue. A negative coverage change, more prior authorization, or lower PAMA rates could hurt revenue and margin.
Growth slows after a strong Q1
Medium impact · Medium oddsQ1 2026 revenue grew 21%, but management's raised full-year guide calls for 13% to 14% revenue growth. That means later quarters may grow more slowly. If the core tests cool at the same time new products ramp slowly, the growth score can fade.
LDT regulation adds cost and delay
Medium impact · Medium oddsThe FDA's 2024 rule phases out broad enforcement discretion for many laboratory developed tests over four years. Existing tests may have some protection, but newer tests could face more review. That can raise costs and stretch launch timelines.
MRD competition and IP fights
Medium impact · Medium oddsThe MRD market is competitive and legally active. Veracyte names Natera as a main competitor in muscle-invasive bladder cancer. If rivals win doctors faster or IP disputes limit Veracyte's whole-genome approach, TrueMRD's upside could shrink.
Israel operating risk
Medium impact · Low oddsThe C2i Genomics acquisition gave Veracyte operations in Israel. The company warns that conflict in the Middle East could interrupt or suspend that site without warning. This matters most for TrueMRD development and operations.
In one breath
What does Veracyte actually sell?
Veracyte sells genomic cancer tests. These tests read patterns in tumor or tissue samples to help doctors decide whether a patient needs more treatment, can avoid treatment, or may have cancer returning.
Why is Decipher important to Veracyte?
Decipher Prostate is the company's main growth engine. It benefits from clinical evidence, guideline support, and a growing base of doctors ordering it for prostate cancer decisions.
Why does reimbursement matter so much?
Most Veracyte revenue comes from tests that need payment from Medicare, insurers, or patients. If payers cut rates or deny more claims, revenue and profit can fall even when doctors order tests.
Is Veracyte profitable now?
Yes, Q1 2026 showed strong profitability, with net income of $28.7 million and cash from operations of $35.2 million. The question is whether that level can hold while the company invests in Prosigna, TrueMRD, and other future tests.